The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 30 December 2003, www.theannals.com, DOI 10.1345/aph.1D223.
 The Annals of Pharmacotherapy: Vol. 38, No. 2, pp. 320-324. DOI 10.1345/aph.1D223
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gibbs, W. J
Right arrow Articles by Hagemann, T. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibbs, W. J
Right arrow Articles by Hagemann, T. M

NEW DRUG DEVELOPMENT

Purified Poloxamer 188 for Sickle Cell Vaso-Occlusive Crisis

Winter J Gibbs, PharmD

Pharmacy Practice Resident, Department of Pharmacy, Parkland Health and Hospital System, Dallas, TX

Tracy M Hagemann, PharmD

Associate Professor of Pharmacy Practice, Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Oklahoma City, OK

Reprints: Tracy M Hagemann PharmD, Department of Pharmacy: Clinical and Administrative Sciences, 1110 N. Stonewall Ave., Oklahoma City, OK 73117-1200, fax 405/271-6430, Tracy-Hagemann{at}ouhsc.edu

OBJECTIVE: To review available literature on the pharmacology, pharmacokinetics, efficacy, toxicology, adverse effects, drug interactions, and dosage guidelines for purified poloxamer 188, a product in Phase III trials.

DATA SOURCES: Reviewers searched the following databases for English-language studies: MEDLINE (1966–November 2003), International Pharmaceutical Abstracts (1970–November 2003), and the Cochrane Library Database (3rd quarter 2003). Key search terms included purified poloxamer 188, Flocor, CRL-5861, poloxamer 188, RheothRx, and pluronic F-68.

STUDY SELECTION AND DATA EXTRACTION: Data on efficacy, adverse effects, and pharmacokinetics were obtained from randomized, open-label, and blinded clinical trials. Toxicology data were obtained from unpublished studies with purified poloxamer 188 and from available data on poloxamer 188 (nonpurified form).

DATA SYNTHESIS: Purified poloxamer 188 is a highly purified form of the nonionic block copolymer poloxamer 188. It lowers blood viscosity, decreases red blood cell (RBC) aggregation, and decreases friction between RBCs and vessel walls to increase microvascular blood flow and decrease cell injury. In clinical trials, purified poloxamer 188 demonstrated safety, but little efficacy for the treatment of sickle cell vaso-occlusive crisis. Increased efficacy has been shown in patients on concurrent hydroxyurea therapy and those <15 years of age.

CONCLUSIONS: Purified poloxamer 188 represents a new approach to the management of the sickle cell vaso-occlusive crisis. Children and patients on hydroxyurea may benefit most from purified poloxamer 188 therapy. Further studies are needed to confirm its efficacy and to determine whether the drug decreases sickle cell disease severity and complications.

Key Words: CRL-5861, Flocor, purified poloxamer 188, sickle cell vaso-occlusive crisis

Published Online, December 30, 2003. www.theannals.com, DOI 10.1345/aph.1D223




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.